ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
8 hedge funds and large institutions have $11M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
60% less capital invested
Capital invested by funds: $27.6M → $11M (-$16.7M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$148K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSCM
Prince Street Capital Management
New York
|
-$2.55M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$172K |
| 3 |
Millennium Management
New York
|
-$86.4K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$80K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $5.12M | – | – | – |
|
|
2
HSBC Holdings
London,
United Kingdom
| $1.93M | -$172K | -770 | -5% |
|
3
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $1.78M | – | – | – |
|
|
PIM
4
Platinum Investment Management
Sydney Australia 2000,
Australia
| $1.02M | – | – | – |
|
|
PSCM
5
Prince Street Capital Management
New York
| $920K | -$2.55M | -11,391 | -64% |
|
|
FIA
6
FNY Investment Advisers
New York
| $104K | +$148K | +660 | New |
|
|
7
Millennium Management
New York
| $72K | -$86.4K | -386 | -46% |
|
|
8
UBS Group
Zurich,
Switzerland
| $14K | +$21K | +94 | New |
|
|
MA
9
MYDA Advisors
Woodmere,
New York
| – | -$80K | -250 | Closed |
|
ASLN Hedge Fund Activity: Q4 2018 in Review
8 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q4 2018, worth a combined $11M — down 60% from $27.6M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ASLN positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $148K. The largest seller was Prince Street Capital Management, cutting an estimated $2.55M.
- 8 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q4 2018, up from 7 in Q3 2018.
- Funds reported $11M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q4 2018, down 60% quarter-over-quarter.
- 2 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q4 2018 was FNY Investment Advisers, an estimated $148K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q4 2018 was Prince Street Capital Management, an estimated $2.55M sold.
Based on aggregated 13F filings for Q4 2018.